ZYZhu Yang

Zhu Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhu Yang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Lianyan Wang

    Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China

    2 shared publications
  • Yongjie Chi

    Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China

    2 shared publications
  • Jiaxin Bao

    Key Laboratory of Green Process and Engineering, State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China

    1 shared publication
  • Jing Zhang

    Key Laboratory of Green Process and Engineering, State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China

    1 shared publication
  • Juan Ma

    Department of Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China

    1 shared publication
  • Shulan Han

    School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China

    1 shared publication

Latest Publications

  • Open Access

    Tumor Microenvironment Regulation and Cancer Targeting Therapy Based on Nanoparticles

    by Shulan Han, Yongjie Chi, Zhu Yang, Juan Ma, Lianyan Wang

    Although we have made remarkable achievements in cancer awareness and medical technology, there are still tremendous increases in cancer incidence and mortality. However, most anti-tumor strategies, including immunotherapy, show low efficiency in clinical application. More and more evidence suggest that this low efficacy may be closely related to the immunosuppression of the tumor microenvironment (TME). The TME plays a significant role in tumorigenesis, development, and metastasis. Therefore, it is necessary to regulate the TME during antitumor therapy. Several strategies are developing to regulate the TME as inhibiting tumor angiogenesis, reversing tumor associated macrophage (TAM) phenotype, removing T cell immunosuppression, and so on. Among them, nanotechnology shows great potential for delivering regulators into TME, which further enhance the antitumor therapy efficacy. Properly designed nanomaterials can carry regulators and/or therapeutic agents to eligible locations or cells to trigger specific immune response and further kill tumor cells. Specifically, the designed nanoparticles could not only directly reverse the primary TME immunosuppression, but also induce effective systemic immune response, which would prevent niche formation before metastasis and inhibit tumor recurrence. In this review, we summarized the development of nanoparticles (NPs) for anti-cancer therapy, TME regulation, and tumor metastasis inhibition. We also discussed the prospect and potential of nanocarriers for cancer therapy.


  • Open Access

    Virus-like Particles for TEM Regulation and Antitumor Therapy

    by Zhu Yang, Yongjie Chi, Jiaxin Bao, Xin Zhao, Jing Zhang, Lianyan Wang

    Tumor development and metastasis are intimately associated with the tumor microenvironment (TME), and it is difficult for vector-restricted drugs to act on the TME for long-term cancer immunotherapy. Virus-like particles (VLPs) are nanocage structures self-assembled from nucleic acid free viral proteins. Most VLPs range from 20–200 nm in diameter and can naturally drain into lymph nodes to induce robust humoral immunity. As natural nucleic acid nanocarriers, their surfaces can also be genetically or chemically modified to achieve functions such as TME targeting. This review focuses on the design ideas of VLP as nanocarriers and the progress of their research in regulating TME.